$42.4 Million is the total value of CHI Advisors LLC's 13 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 8.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ORTX | Buy | ORCHARD THERAPEUTICS PLCads | $22,306,000 | -45.2% | 2,962,267 | +0.1% | 52.57% | +71.3% |
| DTIL | Buy | PRECISION BIOSCIENCES INC | $5,672,000 | -53.7% | 940,560 | +6.6% | 13.37% | +44.6% |
| LVGO | Sell | LIVONGO HEALTH INC | $2,568,000 | -96.1% | 90,000 | -96.6% | 6.05% | -87.9% |
| OVID | Sell | OVID THERAPEUTICS INC | $2,469,000 | -29.5% | 828,413 | -1.8% | 5.82% | +120.2% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $2,105,000 | +1.1% | 36,000 | +38.5% | 4.96% | +215.8% |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $2,001,000 | +223.3% | 458,887 | +197.5% | 4.72% | +909.9% |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $1,749,000 | +6.4% | 39,362 | +2.2% | 4.12% | +232.4% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $805,000 | -49.4% | 15,750 | -21.2% | 1.90% | +58.2% |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $768,000 | -61.9% | 364,132 | -1.7% | 1.81% | +19.2% |
| MYOK | Buy | MYOKARDIA INC | $703,000 | -3.6% | 15,000 | +50.0% | 1.66% | +201.3% |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $623,000 | – | 63,750 | +100.0% | 1.47% | – |
| UMRX | UNUM THERAPEUTICS INC | $389,000 | -42.6% | 940,805 | 0.0% | 0.92% | +79.5% | |
| BLUE | Sell | BLUEBIRD BIO INC | $276,000 | -60.7% | 6,000 | -25.0% | 0.65% | +22.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PRECISION BIOSCIENCES INC | 17 | Q3 2023 | 13.4% |
| OVID THERAPEUTICS INC | 17 | Q3 2023 | 5.8% |
| CORVUS PHARMACEUTICALS INC | 16 | Q2 2023 | 1.8% |
| KEZAR LIFE SCIENCES INC | 15 | Q1 2023 | 5.8% |
| PLIANT THERAPEUTICS INC | 14 | Q3 2023 | 29.2% |
| REPARE THERAPEUTICS INC | 14 | Q3 2023 | 30.3% |
| ORCHARD THERAPEUTICS PLC | 14 | Q4 2022 | 52.6% |
| LARIMAR THERAPEUTICS INC | 14 | Q3 2023 | 9.1% |
| KEROS THERAPEUTICS INC | 14 | Q3 2023 | 8.6% |
| INOZYME PHARMA INC | 13 | Q3 2023 | 9.4% |
View CHI Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | February 13, 2023 | 2,384,402 | 5.1% |
| Cullinan Oncology, Inc. | February 13, 2023 | 3,317,544 | 7.2% |
| Freeline Therapeutics Holdings plc | February 13, 2023 | 4,814,419 | 7.4% |
| Inozyme Pharma, Inc. | February 13, 2023 | 2,204,876 | 5.5% |
| Larimar Therapeutics, Inc. | February 13, 2023 | 3,473,366 | 8.0% |
| Oncorus, Inc. | February 13, 2023 | 2,367,436 | 9.1% |
| Orchard Therapeutics plc | February 13, 2023 | 7,987,396 | 6.3% |
| PLIANT THERAPEUTICS, INC. | February 13, 2023 | 3,199,892 | 6.6% |
| Repare Therapeutics Inc. | February 13, 2023 | 2,800,126 | 6.7% |
| VectivBio Holding AG | February 13, 2023 | 5,492,893 | 8.8% |
View CHI Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR/A | 2023-08-22 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
| SC 13G/A | 2023-02-13 |
View CHI Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.